Yesid Alvarado - Valero, M.D.

Peer-Reviewed Articles

1. Venugopal S, Maiti A, DiNardo CD, Qiao W, Ning J, Loghavi S, Daver NG, Kadia TM, Rausch CR, Alvarado Y , Ohanian M, Sasaki K, Short NJ, Takahashi K, Yilmaz M, Ravandi F, Kantarjian HM, Konopleva MY. Prognostic impact of conventional cytogenetics in acute myeloid leukemia treated with venetoclax and decitabine. Leuk Lymphoma 62(14):3501-3505, 2021. e-Pub 2021. PMID: 34474640.
2. Kim K, Maiti A, Loghavi S, Pourebrahim R, Kadia TM, Rausch CR, Furudate K, Daver NG, Alvarado Y, Ohanian M, Sasaki K, Short NJ, Takahashi K, Yilmaz M, Tang G, Ravandi F, Kantarjian HM, DiNardo CD, Konopleva MY. Outcomes of TP53-mutant acute myeloid leukemia with decitabine and venetoclax. Cancer 127(20):3772-3781, 2021. e-Pub 2021. PMID: 34255353.
3. DiNardo CD, Lachowiez CA, Takahashi K, Loghavi S, Xiao L, Kadia T, Daver N, Adeoti M, Short NJ, Sasaki K, Wang S, Borthakur G, Issa G, Maiti A, Alvarado Y, Pemmaraju N, Montalban Bravo G, Masarova L, Yilmaz M, Jain N, Andreeff M, Jabbour E, Garcia-Manero G, Kornblau S, Ravandi F, Konopleva MY, Kantarjian HM. Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia. J Clin Oncol 39(25):JCO2003736, 2021. e-Pub 2021. PMID: 34043428.
4. Swaminathan M, Kantarjian HM, Levis M, Guerra V, Borthakur G, Alvarado Y, DiNardo CD, Kadia T, Garcia-Manero G, Ohanian M, Daver N, Konopleva M, Pemmaraju N, Ferrajoli A, Andreeff M, Jain N, Estrov Z, Jabbour EJ, Wierda WG, Pierce S, Pinsoy MR, Xiao L, Ravandi F, Cortes JE. A phase I/II study of the combination of quizartinib with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Haematologica 106(8):2121-2130, 2021. e-Pub 2021. PMID: 33853292.
5. Jain N, Keating M, Thompson P, Ferrajoli A, Burger JA, Borthakur G, Takahashi K, Estrov Z, Sasaki K, Fowler N, Kadia T, Konopleva M, Alvarado Y , Yilmaz M, DiNardo C, Bose P, Ohanian M, Pemmaraju N, Jabbour E, Kanagal-Shamanna R, Patel K, Wang W, Jorgensen J, Wang SA, Garg N, Wang X, Wei C, Cruz N, Ayala A, Plunkett W, Kantarjian H, Gandhi V, Wierda WG. Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia: A Nonrandomized Phase 2 Trial. JAMA Oncol 7(8):1213-1219, 2021. e-Pub 2021. PMID: 34110383.
6. Kadia TM, Reville PK, Borthakur G, Yilmaz M, Kornblau S, Alvarado Y, DiNardo CD, Daver N, Jain N, Pemmaraju N, Short N, Wang SA, Tidwell RSS, Islam R, Konopleva M, Garcia-Manero G, Ravandi F, Kantarjian HM. Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial. Lancet Haematol 8(8):e552-e561, 2021. PMID: 34329576.
7. Chien KS, Kim K, Nogueras-Gonzalez GM, Borthakur G, Naqvi K, Daver NG, Montalban-Bravo G, Cortes JE, DiNardo CD, Jabbour E, Alvarado Y, Andreeff M, Bose P, Jain N, Kadia TM, Huang X, Sheppard KB, Klingner-Winton C, Pierce SA, Dong XQ, Soltysiak KA, Kantarjian HM, Garcia-Manero G. Phase II study of azacitidine with pembrolizumab in patients with intermediate-1 or higher-risk myelodysplastic syndrome. Br J Haematol. e-Pub 2021. PMID: 34340254.
8. Maiti A, DiNardo CD, Qiao W, Kadia TM, Jabbour EJ, Rausch CR, Daver NG, Short NJ, Borthakur G, Pemmaraju N, Yilmaz M, Alvarado Y, Montalbano KS, Wade A, Maduike RE, Guerrero JA, Vaughan K, Bivins CA, Pierce S, Ning J, Ravandi F, Kantarjian HM, Konopleva MY. Ten-day decitabine with venetoclax versus intensive chemotherapy in relapsed or refractory acute myeloid leukemia: A propensity score-matched analysis. Cancer. e-Pub 2021. PMID: 34343352.
9. Rausch CR, DiNardo CD, Maiti A, Jammal NJ, Kadia TM, Marx KR, Borthakur G, Savoy JM, Pemmaraju N, DiPippo AJ, Daver NG, Chew SM, Sasaki K, Issa GC, Short NJ, Takahashi K, Ohanian MN, Ning J, Xiao L, Alvarado Y , Kontoyiannis DP, Ravandi F, Kantarjian HM, Konopleva MY. Duration of cytopenias with concomitant venetoclax and azole antifungals in acute myeloid leukemia. Cancer 127(14):2489-2499, 2021. e-Pub 2021. PMID: 33793970.
10. Jabbour E, Sasaki K, Short NJ, Ravandi F, Huang X, Khoury JD, Kanagal-Shamanna R, Jorgensen J, Khouri IF, Kebriaei P, Jain N, Alvarado Y , Kadia TM, Paul S, Garcia-Manero G, Dabaja BS, Burger JA, DiNardo CD, Daver NA, Montalban-Bravo G, Yilmaz M, Ohanian M, Ferrajoli A, Jacob J, Rostykus M, Garris R, O'Brien S, Kantarjian HM. Long-term follow-up of salvage therapy using a combination of inotuzumab ozogamicin and mini-hyper-CVD with or without blinatumomab in relapsed/refractory Philadelphia chromosome-negative acute lymphoblastic leukemia. Cancer 127(12):2025-2038, 2021. e-Pub 2021. PMID: 33740268.
11. Venugopal S, Maiti A, DiNardo CD, Loghavi S, Daver NG, Kadia TM, Rausch CR, Alvarado Y , Ohanian M, Sasaki K, Short NJ, Takahashi K, Yilmaz M, Ravandi F, Kantarjian HM, Konopleva MY. Decitabine and venetoclax for IDH1/2-mutated acute myeloid leukemia. Am J Hematol 96(5):E154-E157, 2021. e-Pub 2021. PMID: 33580980.
12. Lachowiez CA, Loghavi S, Furudate K, Montalban-Bravo G, Maiti A, Kadia T, Daver N, Borthakur G, Pemmaraju N, Sasaki K, Alvarado Y , Yilmaz M, Short NJ, Chien K, Ohanian M, Pierce S, Patel KP, Jabbour E, Ravandi F, Kantarjian HM, Garcia-Manero G, Takahashi K, Konopleva MY, DiNardo CD. Impact of splicing mutations in acute myeloid leukemia treated with hypomethylating agents combined with venetoclax. Blood Adv 5(8):2173-2183, 2021. PMID: 33885753.
13. Maiti A, Rausch CR, Cortes JE, Pemmaraju N, Daver NG, Ravandi F, Garcia-Manero G, Borthakur G, Naqvi K, Ohanian M, Short NJ, Alvarado Y , Kadia TM, Takahashi K, Yilmaz M, Jain N, Kornblau S, Montalban Bravo G, Sasaki K, Andreeff M, Bose P, Ferrajoli A, Issa GC, Jabbour EJ, Masarova L, Thompson PA, Wang S, Konoplev S, Pierce SA, Ning J, Qiao W, Welch JS, Kantarjian HM, DiNardo CD, Konopleva MY. Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens. Haematologica 106(3):894-898, 2021. e-Pub 2021. PMID: 32499238.
14. Maiti A, Qiao W, Sasaki K, Ravandi F, Kadia TM, Jabbour EJ, Daver NG, Borthakur G, Garcia-Manero G, Pierce SA, Montalbano KS, Pemmaraju N, Naqvi K, Ohanian M, Short NJ, Alvarado Y , Takahashi K, Yilmaz M, Jain N, Kornblau SM, Andreeff M, Bose P, Ferrajoli A, Issa GC, Masarova L, Thompson PA, Rausch CR, Ning J, Kantarjian HM, DiNardo CD, Konopleva MY. Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: A propensity score matched analysis stratified by risk of treatment-related mortality. Am J Hematol 96(3):282-291, 2021. e-Pub 2020. PMID: 33264443.
15. Reville PK, Kantarjian HM, Ravandi F, Jabbour E, DiNardo CD, Daver N, Pemmaraju N, Ohanian M, Alvarado Y , Xiao L, Alatrash G, Loghavi S, Rausch CR, Borthakur G, Konopleva M, Cortes J, Kadia TM. Nivolumab maintenance in high-risk acute myeloid leukemia patients: a single-arm, open-label, phase II study. Blood Cancer J 11(3):60, 2021. e-Pub 2021. PMID: 33731681.
16. Ravandi F, Pierce S, Garcia-Manero G, Kadia T, Jabbour E, Borthakur G, DiNardo CD, Daver N, Short NJ, Alvarado Y , Cortes J, Kim C, Kelsh M, Katz A, Williams R, Yang Z, Mehta B, Kantarjian H. Salvage Therapy Outcomes in a Historical Cohort of Patients With Relapsed or Refractory Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk 20(11):e871-e882, 2020. e-Pub 2020. PMID: 32792304.
17. Issa GC, Kantarjian HM, Xiao L, Ning J Alvarado Y, , Borthakur G, Daver N, DiNardo CD, Jabbour E, Bose P, Jain N, Kadia TM, Naqvi K, Pemmaraju N, Takahashi K, Verstovsek S, Andreeff M, Kornblau SM, Estrov Z, Ferrajoli A, Garcia-Manero G, Ohanian M, Wierda WG, Ravandi F, Cortes JE. Phase II trial of CPX-351 in patients with acute myeloid leukemia at high risk for induction mortality. Leukemia 34(11):2914-2924, 2020. e-Pub 2020. PMID: 32546726.
18. Chifotides HT, Masarova L, Alfayez M, Daver N, Alvarado Y , Jabbour E, Konopleva M, Kantarjian HM, Patel KP, DiNardo CD, Verstovsek S. Outcome of patients with IDH1/2-mutated post-myeloproliferative neoplasm AML in the era of IDH inhibitors. Blood Adv 4(21):5336-5342, 2020. PMID: 33112940.
19. Sasaki K, Jabbour E, Naqvi K, Skinner J, Anderson K, Dellasala E. S, Yilmaz M, Ferrajoli A, Bose P, Thompson A. P, Alvarado Y, Jain N, Garcia- Manero G, Takahashi K, Burger A. J, Borthakur G, Pemmaraju N, Khouri R, Paul S, Pierce A. S, Cortes E. J, Kantarjian M. K. The Comparison of Frontline Lower-Dose Dasatinib 50 Mg/Day to Standard-Dose Dasatinib 100 Mg/Day in Newly Diagnosed Chronic Myeloid Leukemia: A Propensity Score Analysis. Blood 136(Suppl 1):3-5, 2020.
20. Short N, Kantarjian M. H, Ravandi F, Huang X, Ferrajoli A, Kadia M. T, Thompson A. P, Alvarado Y, Jain N, Yilmaz M, Khoury D. J, Jorgensen L. J, Wang A. Sa, Kornblau M. S, Konopleva M, Garcia - Manero G, Schroeder M. H, Kwari M, Paul S, Nwakanme B, Loiselle C, Garris R, O'Brien M. S,Jabbour E. Hyper-CVAD and Sequential Blinatumomab in Adults with Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia: Results from a Phase II Study. 62nd Annual Meeting & Exposition. Blood 136(Suppl 1):9-11, 2020.
21. DiNardo CD, Maiti A, Rausch CR, Pemmaraju N, Naqvi K, Daver NG, Kadia TM, Borthakur G, Ohanian M Alvarado Y, , Issa GC, Montalban-Bravo G, Short NJ, Yilmaz M, Bose P, Jabbour EJ, Takahashi K, Burger JA, Garcia-Manero G, Jain N, Kornblau SM, Thompson PA, Estrov Z, Masarova L, Sasaki K, Verstovsek S, Ferrajoli A, Weirda WG, Wang SA, Konoplev S, Chen Z, Pierce SA, Ning J, Qiao W, Ravandi F, Andreeff M, Welch JS, Kantarjian HM, Konopleva MY. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial. Lancet Haematol 7(10):e724-e736, 2020. e-Pub 2020. PMID: 32896301.
22. Bose P, Verstovsek S, Cortes JE, Tse S, Gasior Y, Jain N, Jabbour EJ, Estrov Z Alvarado Y, , DiNardo CD, Pemmaraju N, Kornblau SM, Kadia TM, Daver NG, Naqvi K, Short NJ, Masarova L, Villareal J, Pierce SA, Nogueras-Gonzalez G, Huang X, Garcia-Manero G, Kantarjian HM, Ravandi F. A phase 1/2 study of ruxolitinib and decitabine in patients with post-myeloproliferative neoplasm acute myeloid leukemia. Leukemia 34(9):2489-2492, 2020. e-Pub 2020. PMID: 32099037.
23. Garcia-Manero G, Pemmaraju N, Alvarado Y , Naqvi K, Ravandi F, Jabbour E, De Lumpa R, Kantarjian H, Advani A, Mukherjee S, Gerds A, Carraway HE, Nazha A, Iwamura H, Murase M, Bavisotto L, Kurman M, Maier G, Johansen M, Sekeres MA. Results of a Phase 1/2a dose-escalation study of FF-10501-01, an IMPDH inhibitor, in patients with acute myeloid leukemia or myelodysplastic syndromes. Leuk Lymphoma 61(8):1943-1953, 2020. e-Pub 2020. PMID: 32264726.
24. Sasaki K, Kantarjian H, Wierda W, Ravandi-Kashani F, Jorgensen J, Wang SA, Khoury J, Daver N, Burger J, Di Nardo CD, Jain N, Short NJ, Estrov Md Z, Konopleva Md PhD M, Ohanian DO M, Garcia-Manero G, Kadia T, Alvarado Y, Yilmaz M, Pierce S, Garris R, Ingram A, Cortes J, O'Brien S, Jabbour E. Phase 2 study of hyper-CMAD with liposomal vincristine for patients with newly diagnosed acute lymphoblastic leukemia. Am J Hematol 95(7):734-739, 2020. e-Pub 2020. PMID: 32170867.
25. Navada SC, Garcia-Manero G, Odchimar Reissig R, Pemmaraju N, Alvarado Y, Ohanian MN, John RB, Demakos EP, Zbyszewski PS, Maniar M, Woodman RC, Fruchtman SM, Silverman LR. Rigosertib in combination with azacitidine in patients with myelodysplastic syndromes or acute myeloid leukemia: Results of a phase 1 study. Leuk Res 94:106369, 2020. e-Pub 2020. PMID: 32442785.
26. Jabbour E, Richard-Carpentier G, Sasaki Y, Konopleva M, Patel K, Roberts K, Gu Z, Wang F, Huang X, Sasaki K, Short NJ, Jain N, Ravandi F, Daver NG, Kadia TM, Alvarado Y , DiNardo CD, Issa GC, Pemmaraju N, Garcia-Manero G, Verstovsek S, Wang S, Khoury JD, Jorgensen J, Champlin R, Khouri I, Kebriaei P, Schroeder H, Khouri M, Mullighan CG, Takahashi K, O'Brien SM, Kantarjian H. Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia: a single-arm, phase 2 trial. Lancet Haematol 7(7):e523-e533, 2020. PMID: 32589978.
27. Richard-Carpentier G, Jabbour E, Short NJ, Rausch CR, Savoy JM, Bose P, Yilmaz M, Jain N, Borthakur G, Ohanian M, Alvarado Y , Rytting M, Kebriaei P, Konopleva M, Kantarjian H, Ravandi F. Clinical Experience with Venetoclax Combined With Chemotherapy for Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk 20(4):212-218, 2020. e-Pub 2019. PMID: 32035785.
28. Lachowiez CA, Loghavi S, Kadia TM, Daver N, Borthakur G, Pemmaraju N, Naqvi K, Alvarado Y , Yilmaz M, Short N, Ohanian M, Pierce SR, Patel KP, Qiao W, Ning J, Sasaki K, Takahashi K, Jabbour E, Andreeff M, Ravandi F, Kantarjian HM, Konopleva M, DiNardo CD. Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens. Blood Adv 4(7):1311-1320, 2020. PMID: 32251497.
29. Montalban-Bravo G, Kanagal-Shamanna R, Benton CB, Class CA, Chien KS, Sasaki K, Naqvi K, Alvarado Y , Kadia TM, Ravandi F, Daver N, Takahashi K, Jabbour E, Borthakur G, Pemmaraju N, Konopleva M, Soltysiak KA, Pierce SR, Bueso-Ramos CE, Patel KP, Kantarjian H, Garcia-Manero G. Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes. Blood Adv 4(3):482-495, 2020. PMID: 32027746.
30. Naqvi K, Jabbour E, Skinner J, Anderson K, Dellasala S, Yilmaz M, Ferrajoli A, Bose P, Thompson P, , Alvarado Y Jain N, Takahashi K, Burger J, Estrov Z, Borthakur G, Pemmaraju N, Paul S, Cortes J, Kantarjian HM. Long-term follow-up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia. Cancer 126(1):67-75, 2020. e-Pub 2019. PMID: 31553487.
31. Bannon SA, Routbort MJ, Montalban-Bravo G, Mehta RS, Jelloul FZ, Takahashi K, Daver N, Oran B, Pemmaraju N, Borthakur G, Naqvi K, Issa G, Sasaki K Alvarado Y, , Kadia TM, Konopleva M, Shamanna RK, Khoury JD, Ravandi F, Champlin R, Kantarjian HM, Bhalla K, Garcia-Manero G, Patel KP, DiNardo CD. Next-Generation Sequencing of DDX41 in Myeloid Neoplasms Leads to Increased Detection of Germline Alterations. Front Oncol 10:582213, 2020. e-Pub 2021. PMID: 33585199.
32. Jain N, Keating MJ, Thompson PA, Ferrajoli A, Burger JA, Borthakur GM, Takahashi K, Estrov ZE, Fowler NH, Kadia TM, Konopleva MY, Alvarado Y , Yilmaz M, DiNardo CD, Bose P, Ohanian M, Pemmaraju N, Jabbour E, Sasaki K, Kanagal-Shamanna R, Patel K, Jorgensen JL, Wang SA, Garg N, Wang X, Sondermann K, Cruz N, Wei C, Ayala A, Plunkett W, Kantarjian HM, Gandhi V, Wierda WG. Combined Ibrutinib and Venetoclax for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL). Blood 134(Supplement_1):34, 2019. PMID: 31724006.
33. Swaminathan M, Borthakur G, Kadia TM, Ferrajoli A, Alvarado Y , Pemmaraju N, Bodden K, Yearby B, Konopleva M, Khoury J, Bueso-Ramos C, Garcia-Manero G, DiNardo CD. A phase 2 clinical trial of eltrombopag for treatment of patients with myelodysplastic syndromes after hypomethylating-agent failure. Leuk Lymphoma 18(9):1-7, 2019. e-Pub 2019. PMID: 30773968.
34. Ravandi F, Assi R, Daver N, Benton CB, Kadia T, Thompson PA, Borthakur G, Alvarado Y , Jabbour EJ, Konopleva M, Takahashi K, Kornblau S, DiNardo CD, Estrov Z, Flores W, Basu S, Allison J, Sharma P, Pierce S, Pike A, Cortes JE, Garcia-Manero G, Kantarjian HM. Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study. Lancet Haematol 6(9):e480-e488, 2019. e-Pub 2019. PMID: 31400961.
35. Bose P, Swaminathan M, Pemmaraju N, Ferrajoli A, Jabbour EJ, Daver NG, DiNardo CD, Alvarado Y, Yilmaz M, Huynh-Lu J, Qiao W, Wang X, Matamoros A, Zhou L, Pierce S, Schroeder KD, Kantarjian HM, Verstovsek S. A phase 2 study of pracinostat combined with ruxolitinib in patients with myelofibrosis. Leuk Lymphoma 60(7):1-8, 2019. e-Pub 2019. PMID: 30632841.
36. Strati P, Garcia-Manero G, Zhao C, Kadia T, Borthakur G, Konopleva M, Daver N, DiNardo CD, Short NJ, Yilmaz M, Naqvi K, Alvarado Y , Pierce SA, Cortes J, Bueso-Ramos C, Kantarjian H, Ravandi F. Intensive chemotherapy is more effective than hypomethylating agents for the treatment of younger patients with myelodysplastic syndrome and elevated bone marrow blasts. Am J Hematol 94(7):E188-E190, 2019. e-Pub 2019. PMID: 30977182.
37. Jain N, Keating M, Thompson P, Ferrajoli A, Burger J, Borthakur G, Takahashi K, Estrov Z, Fowler N, Kadia T, Konopleva M, Alvarado Y , Yilmaz M, DiNardo C, Bose P, Ohanian M, Pemmaraju N, Jabbour E, Sasaki K, Kanagal-Shamanna R, Patel K, Jorgensen J, Garg N, Wang X, Sondermann K, Cruz N, Wei C, Ayala A, Plunkett W, Kantarjian H, Gandhi V, Wierda W. Ibrutinib and Venetoclax for First-Line Treatment of CLL. N Engl J Med 380(22):2095-2103, 2019. PMID: 31141631.
38. Maiti A, Naqvi K, Kadia TM, Borthakur G, Takahashi K, Bose P, Daver NG, Patel A, Alvarado Y, Ohanian M, DiNardo CD, Cortes JE, Jabbour EJ, Garcia-Manero G, Kantarjian HM, Ravandi F. Phase II Trial of MEK Inhibitor Binimetinib (MEK162) in RAS-mutant Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk 19(3):142-148.e1, 2019. e-Pub 2018. PMID: 30635233.
39. Benton CB, Chien KS, Tefferi A, Rodriguez J, Ravandi F, Daver N, Jabbour E, Jain N, Alvarado Y, Kwari M, Pierce S, Maiti A, Hornbaker M, Santos MA, Martinez S, Siguero M, Zblewski D, Al-Kali A, Hogan WJ, Kantarjian H, Pardanani A, Garcia-Manero G. Safety and tolerability of lurbinectedin (PM01183) in patients with acute myeloid leukemia and myelodysplastic syndrome. Hematol Oncol 37(1):96-102, 2019. e-Pub 2018. PMID: 30153704.
40. Swaminathan M, Bannon SA, Routbort M, Naqvi K, Kadia TM, Takahashi K, Alvarado Y, Ravandi-Kashani F, Patel KP, Champlin R, Kantarjian H, Strong L, DiNardo CD. Hematologic malignancies and Li-Fraumeni syndrome. Cold Spring Harb Mol Case Stud 5(1), 2019. e-Pub 2019. PMID: 30709875.
41. Short NJ, Jabbour E, Naqvi K, Patel A, Ning J, Sasaki K, Nogueras-Gonzalez GM, Bose P, Kornblau SM, Takahashi K, Andreeff M, Sanchez-Petitto G, Estrov Z, Dinardo CD, Montalban-Bravo G, Konopleva M, Alvarado Y, Bhalla KN, Fiskus W, Khouri M, Islam R, Kantarjian H, Garcia-Manero G. A phase II study of omacetaxine mepesuccinate for patients with higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia after failure of hypomethylating agents. Am J Hematol 94(1):74-79, 2019. e-Pub 2018. PMID: 30328139.
42. Short NJ, Kantarjian HM, Loghavi S, Huang X, Qiao W, Borthakur G, Kadia TM, Daver N, Ohanian M, Dinardo CD, Estrov Z, Kanagal-Shamanna R, Maiti A, Benton CB, Bose P, Alvarado Y, Jabbour E, Kornblau SM, Pemmaraju N, Jain N, Gasior Y, Richie MA, Pierce S, Cortes J, Konopleva M, Garcia-Manero G, Ravandi F. Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial. Lancet Haematol 6(1):e29-e37, 2019. e-Pub 2018. PMID: 30545576.
43. Assi R, Garcia-Manero G, Ravandi F, Borthakur G, Daver NG, Jabbour E, Burger J, Estrov Z, Dinardo CD, Alvarado Y, Hendrickson S, Ferrajoli A, Wierda W, Cortes J, Kantarjian H, Kadia TM. Addition of eltrombopag to immunosuppressive therapy in patients with newly diagnosed aplastic anemia. Cancer 124(21):4192-4201, 2018. e-Pub 2018. PMID: 30307606.
44. Abaza Y, Hidalgo-Lopez JE, Verstovsek S, Jabbour E, Ravandi F, Borthakur G, Estrov Z, Alvarado Y, Burger J, Schneider H, Soltysiak KA, Wei Y, Kantarjian HM, Bueso-Ramos CE, Garcia-Manero G. Phase I study of ruxolitinib in previously treated patients with low or intermediate-1 risk myelodysplastic syndrome with evidence of NF-kB activation. Leuk Res 73:78-85, 2018. e-Pub 2018. PMID: 30245189.
45. Masarova L, Verstovsek S, Hidalgo-Lopez JE, Pemmaraju N, Bose P, Estrov Z, Jabbour EJ, Ravandi-Kashani F, Takahashi K, Cortes JE, Ning J, Ohanian M, Alvarado Y, Zhou L, Pierce S, Gergis R, Patel KP, Luthra R, Kadia TM, DiNardo CD, Borthakur G, Bhalla K, Garcia-Manero G, Bueso-Ramos CE, Kantarjian HM, Daver N. A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis. Blood 132(16):1664-1674, 2018. e-Pub 2018. PMID: 30185431.
46. Short NJ, Kantarjian H, Jabbour E, Cortes JE, Thomas DA, Rytting ME, Daver N, Alvarado Y, Konopleva M, Kebriaei P, Wierda WG, DiNardo CD, Bivins C, McCue D, Richie MA, Ravandi F. A phase I study of moxetumomab pasudotox in adults with relapsed or refractory B-cell acute lymphoblastic leukaemia. Br J Haematol 182(3):442-444, 2018. e-Pub 2017. PMID: 28616864.
47. Naqvi K, Jabbour E, Skinner J, Yilmaz M, Ferrajoli A, Bose P, Thompson P, Alvarado Y, Jain N, Takahashi K, Burger J, Estrov Z, Borthakur G, Pemmaraju N, Paul S, Cortes J, Kantarjian HM. Early results of lower dose dasatinib (50?mg daily) as frontline therapy for newly diagnosed chronic-phase chronic myeloid leukemia. Cancer 124(13):2740-2747, 2018. e-Pub 2018. PMID: 29723397.
48. Ohanian M, Tari Ashizawa A, Garcia-Manero G, Pemmaraju N, Kadia T, Jabbour E, Ravandi F, Borthakur G, Andreeff M, Konopleva M, Lim M, Pierce S, O'Brien S, Alvarado Y, Verstovsek S, Wierda W, Kantarjian H, Cortes J. Liposomal Grb2 antisense oligodeoxynucleotide (BP1001) in patients with refractory or relapsed haematological malignancies: a single-centre, open-label, dose-escalation, phase 1/1b trial. Lancet Haematol 5(4):e136-e146, 2018. e-Pub 2018. PMID: 29550383.
49. Kantarjian H, Ravandi F, Short NJ, Huang X, Jain N, Sasaki K, Daver N, Pemmaraju N, Khoury JD, Jorgensen J, Alvarado Y, Konopleva M, Garcia-Manero G, Kadia T, Yilmaz M, Bortakhur G, Burger J, Kornblau S, Wierda W, DiNardo C, Ferrajoli A, Jacob J, Garris R, O'Brien S, Jabbour E. Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study. Lancet Oncol 19(2):240-248, 2018. e-Pub 2018. PMID: 29352703.
50. Boddu P, Jorgensen J, Kantarjian H, Borthakur G, Kadia T, Daver N, Alvarado Y, Pemmaraju N, Bose P, Naqvi K, Yilmaz M, Pierce S, Brandt M, DiNardo CD, Jabbour EJ, Konopleva M, Garcia-Manero G, Cortes J, Ravandi F. Achievement of a negative minimal residual disease state after hypomethylating agent therapy in older patients with AML reduces the risk of relapse. Leukemia 32(1):241-244, 2018. e-Pub 2017. PMID: 28919634.
51. Abaza Y, M Kantarjian H, Faderl S, Jabbour E, Jain N, Thomas D, Kadia T, Borthakur G, Khoury JD, Burger J, Wierda W, O'Brien S, Konopleva M, Ferrajoli A, Kebriaei P, Dabaja B, Kornblau S, Alvarado Y , Daver N, Pemmaraju N, Bose P, Thompson P, Al Azzawi H, Kelly M, Garris R, Jain P, Garcia-Manero G, Cortes J, Ravandi F. Hyper-CVAD plus nelarabine in newly diagnosed adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma. Am J Hematol 93(1):91-99, 2018. e-Pub 2017. PMID: 29047158.
52. Abou Dalle I, Cortes JE, Pinnamaneni P, Lamothe B, Diaz Duque A, Randhawa J, Pemmaraju N, Jabbour E, Ferrajoli A, Wierda WG, Estrov Z, Konopleva M, Ravandi F, Alvarado Y, Borthakur G, Gandhi V, Kantarjian HM. A Pilot Phase II Study of Erlotinib for the Treatment of Patients with Relapsed/Refractory Acute Myeloid Leukemia. Acta Haematol 140(1):30-39, 2018. e-Pub 2018. PMID: 30071517.
53. Boddu P, Borthakur G, Koneru M, Huang X, Naqvi K, Wierda W, Bose P, Jabbour E, Estrov Z, Burger J, Alvarado Y, Deshmukh A, Patel A, Cavazos A, Han L, Cortes JE, Kantarjian H, Andreeff M, Konopleva M. Initial Report of a Phase I Study of LY2510924, Idarubicin, and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia. Front Oncol 8:369, 2018. e-Pub 2018. PMID: 30319961.
54. Numan Y, Alfayez M, Maiti A, Alvarado Y, Jabbour EJ, Ferrajoli A, Konoplev SN, Kantarjian HM, Bose P. First report of clinical response to Venetoclax in Early T-cell Precursor Acute Lymphoblastic Leukemia. JCO Precis Oncol 2, 2018. e-Pub 2018. PMID: 31080940.
55. Jabbour E, Short NJ, Montalban-Bravo G, Huang X, Bueso-Ramos C, Qiao W, Yang H, Zhao C, Kadia T, Borthakur G, Pemmaraju N, Sasaki K, Estrov Z, Cortes J, Ravandi F, Alvarado Y, Komrokji R, Sekeres MA, Steensma DP, DeZern A, Roboz G, Kantarjian H, Garcia-Manero G. A randomized phase II study of low-dose decitabine versus low-dose azacitidine in lower risk MDS and MDS/MPN. Blood 130(13):1514-1522, 2017. e-Pub 2017. PMID: 28774880.
56. Montalban-Bravo G, Huang X, Naqvi K, Jabbour E, Borthakur G, DiNardo CD, Pemmaraju N, Cortes J, Verstovsek S, Kadia T, Daver N, Wierda W, Alvarado Y, Konopleva M, Ravandi F, Estrov Z, Jain N, Alfonso A, Brandt M, Sneed T, Chen HC, Yang H, Bueso-Ramos C, Pierce S, Estey E, Bohannan Z, Kantarjian HM, Garcia-Manero G. A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials. Leukemia 31(7):1659, 2017. e-Pub 2017. PMID: 28338082.
57. Montalban-Bravo G, Huang X, Naqvi K, Jabbour E, Borthakur G, DiNardo CD, Pemmaraju N, Cortes J, Verstovsek S, Kadia T, Daver N, Wierda W, Alvarado A , Konopleva M, Ravandi F, Estey E, Alfonso A, Brandt M, Sneed T, Chen HC, Yang H, Bueso-Ramos C, Pierce S, Estey E, Bohannan Z, Kantarjian HM, Garcia-Manero G. A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials. Leukemia 31(2):318-324, 2017. e-Pub 2016. PMID: 27795561.
58. Tang Z, Tang G, Wang SA, Lu X, Young KH, Bueso-Ramos CE, Alvarado Y , Medeiros LJ, Khoury JD. Simultaneous deletion of 3'ETV6 and 5'EWSR1 genes in blastic plasmacytoid dendritic cell neoplasm: case report and literature review. Mol Cytogenet 9:23, 2016. e-Pub 2016. PMID: 26925167.
59. Alvarado Y, Kantarjian HM, Luthra R, Ravandi F, Borthakur G, Garcia-Manero G, Konopleva M, Estrov Z, Andreeff M, Cortes JE. Treatment with FLT3 inhibitor in patients with FLT3-mutated acute myeloid leukemia is associated with development of secondary FLT3-tyrosine kinase domain mutations. Cancer 120(14):2142-9, 2014. e-Pub 2014. PMID: 24737502.
60. Alvarado Y, Giles FJ, Swords RT. The PIM kinases in hematological cancers. Expert Rev Hematol 5(1):81-96, 2012. PMID: 22272708.
61. Alvarado Y, Mita MM, Vemulapalli S, Mahalingam D, Mita AC. Clinical Activity of Mammalian Target of Rapamycin Inhibitors in Solid Tumors. Targeted Oncology 6(2):69-94, 2011. e-Pub 2011.
62. Vemulapalli S, Mita M, Alvarado Y, Sankhala K, Mita A. The emerging role of mammalian target of rapamycin inhibitors in the treatment of sarcomas. Targeted Oncology 6(1):29-39, 2011. e-Pub 2011.
63. Santos FP, Alvarado Y, Kantarjian H, Verma D, O'Brien S, Mattiuzzi G, Ravandi F, Borthakur G, Cortes J. Long-term prognostic impact of the use of erythropoietic-stimulating agents in patients with chronic myeloid leukemia in chronic phase treated with imatinib. Cancer 1(117):982-91, 2011. e-Pub 2010. PMID: 20960502.
64. Alvarado Y, Swords R, Kelly KR, Giles J. Clinical activity of laromustine (Onrigin™) in hematologic malignancies. Expert Review of Hematology 2(5):481-488, 2009.
65. Alvarado Y, Kantarjian H, O’Brien S, Faderl S, Borthakur G, Burger J, Wierda W, Garcia- Manero G, Shan J, Cortes J. Significance of Suboptimal Response to Imatinib, as Defined by the European LeukemiaNet, in Long-Term Outcome for Patients with Early Chronic Phase Chronic Myeloid Leukemia. Cancer 115(16):3709-18, 2009.
66. Alvarado Y, Kantarjian H, O'Brien S, Faderl S, Borthakur G, Burger J, Wierda W, Garcia-Manero G, Shan J, Cortes J. Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in the long-term outcome of patients with early chronic myeloid leukemia in chronic phase. Cancer 115(16):3709-18, 2009. PMID: 19517462.
67. Swords R, Alvarado Y , Giles F. The Current Status of Biphenotypic Leukemia. Myeloproliferative Disorders in Practice 2(2), 2008.
68. Borthakur G, Alvarado Y, Ravandi-Kashani F, Cortes J, Estrov Z, Faderl S, Ivy P, Bueso-Ramos C, Nebiyou Bekele B, Giles F. Phase 1 Study of XL119, a Rebeccamycin Analog, in Patients with Refractory Hematologic Malignancies. Cancer 113(2):360-6, 2008. PMID: 18473351.
69. Alvarado Y, Cortes J. Emerging Role of Aurora Kinase inhibition in Chronic Myeloid Leukemia. Clinical Leukemia 1(6):325-327, 2007.
70. Alvarado Y, Welch MA, Swords R, Bruzzi J, Schelette E, Giles F. Plasma Cell Granuloma: A Case Report of Multiple Lesions in the Lung and Review of the Literature. American Journal of Medical Sciences 334(5):402-6, 2007.
71. Alvarado Y, Jumper C, Hardwicke F, D’Cunha N, Cobos E. Acquired Hemophilia: A Case Report of 2 Patients with Acquired Factor VIII Inhibitor Treated with Rituximab Plus a Short Course of Steroid and Review of the Literature. Clinical and Applied Thrombosis and Hemostasis 13(4):443-8, 2007.
72. Alvarado Y, Giles FJ. Ras as a therapeutic target in hematologic malignancies. Expert Opin Emerg Drugs 12(2):271-84, 2007. PMID: 17604501.
73. Alvarado Y, Welch M, Swords R, Bruzzi J, Schelette E, Giles F. Nelarabine Activity in Acute Biphenotypic Leukemia. Leukemia Research 31(11):1600-1603, 2007.
74. Swords R, Alvarado Y , Cortes J, Giles FJ. Second-generation tyrosine kinase inhibitors as therapy for chronic myeloid leukemia. Curr Hematol Malig Rep 2(2):83-8, 2007. PMID: 20425355.
75. Alvarado Y, Apostolidou E, Swords R, Giles FJ. Emerging therapeutic options for Philadelphia-positive acute lymphocytic leukemia. Expert Opin Emerg Drugs 12(1):165-79, 2007. PMID: 17355221.
76. Swords R, Alvarado Y , Giles F. Novel abl kinase inhibitors in chronic myeloid leukemia in blastic phase and Philadelphia chromosome-positive acute lymphoblastic leukemia. Clinical Lymphoma Myeloma 7(3):S113-9, 2007.
77. Apostolidou E, Swords R, Alvarado Y, Giles FJ. Treatment of Acute Lymphoblastic Leukemia: A New Era?. Drugs 67(15):2153-71, 2007.
78. Angulo F, Alvarado Y , Chokesuwattanaskul W, Roongsritrong C. Troponin I Elevation in a patient with Acute Severe Bronchospasm. The American Journal of the Medical Sciences 329(6), 2005.
79. Giles F, Fracasso P, Kantarjian H, Cortes J, Brown R, Verstovsek S, Alvarado Y, thomas D, Faderl S, Garcia - Manero G, Wright L, Samson T, Cahill A, Lambert P, Plunket W, Sznol M, DiPersio J, Gandhi V. Phase I and pharmacodynamic study of Triapine®, a novel ribonucleotide reductase inhibitor, in patients with advanced leukemia. Leukemia Research 27(12):1077-1083, 2003.
80. Tsimberidou AM, Kantarjian H, Cortes J, Thomas DA, Faderl S, Garcia-Manero G, Verstovsek S, Ferrajoli A, Wierda W, Alvarado Y, O’Brien S, Albitar M, Keating MJ, Giles FJ. Fractionated Cyclophosphamide, Vincristine, Liposomal daunorubicin, and Dexamethasone plus Rituximab and Granulocyte-Macrophage-Colony Stimulating Factor (GM-CSF) Alternating with Methotrexate and cytarabine plus Rituximab and GM-CSF in Patients with Richter’s Syndrome or Fludarabine-Refractory Chronic Lymphocytic Leukemia. Cancer 97(7), 2003.
81. Alvarado Y, Cortes J, Verstovsek S, Thomas D, Faderl S, Estrov Z, Kantarjian H, Giles F. Pilot study of pegylated Interferon-alpha 2b in patients with essential thrombocythemia. Cancer Chemotherapy and Pharmacology 5(1):81-86, 2003.
82. Alvarado Y,Tsimberidou AM, Kantarjian H, Cortes J, Garcia-Manero G, Faderl S, Thomas D, Estey E, Giles FJ. Pilot study of Mylotarg, Idarubicin and Cytarabine combination regimen in patients with primary resistant or relapsed Acute Myeloid Leukemia. Cancer Chemotherapy and Pharmacology 5(1):87-90, 2003.
83. Tsimberidou AM, Alvarado Y, Giles FJ. The Evolving role of ribonucleoside reductase inhibitors in hematologic malignancies. Expert Rev Anticancer Therapy 2(4):437-48, 2002. PMID: 12647987.
84. Alvarado Y, Kantarjian H, Cortes JE, Apostolidou E, Bivins C, Giles FJ. Troxacitabine activity in extramedullary myeloid leukemia. Hematology 7(3):179-185, 2002.
85. Alvarado Y, Bellm LA, Giles FJ. Oral Mucositis: time for more studies. Hematology 7:281-289, 2002.

Abstracts

1. Sasaki K, Jabbour E, Naqvi K, Skinner J, Anderson K, Dellasala E. S, Yilmaz M, Ferrajoli A, Bose P, Thompson A. P, Alvarado Y, Jain N, Garcia- Manero G, Takahashi K, Burger A. J, Borthakur G, Pemmaraju N, Khouri R, Paul S, Pierce A. S, Cortes E. J, Kantarjian M. K. The Comparison of Frontline Lower-Dose Dasatinib 50 Mg/Day to Standard-Dose Dasatinib 100 Mg/Day in Newly Diagnosed Chronic Myeloid Leukemia: A Propensity Score Analysis. 62nd Annual Meeting & Exposition. Blood 136(Suppl 1):3-5, 2020.
2. Short N, Kantarjian M. H, Ravandi F, Huang X, Ferrajoli A, Kadia M. T, Thompson A. P, Alvarado Y, Jain N, Yilmaz M, Khoury D. J, Jorgensen L. J, Wang A. Sa, Kornblau M. S, Konopleva M, Garcia - Manero G, Schroeder M. H, Kwari M, Paul S, Nwakanme B, Loiselle C, Garris R, O'Brien M. S,Jabbour E. Hyper-CVAD and Sequential Blinatumomab in Adults with Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia: Results from a Phase II Study. 62nd Annual Meeting & Exposition. Blood 136(Suppl 1):9-11, 2020.
3. Morita K, Naqvi K, Montalban Bravo G, Thompson A. P, Takahashi K, Alvarado Y, Jabbour E, Kantarjian M. H, Garcia - Manero G. Initial Results of a Phase I/II Study of Venetoclax in Combination with Azacitidine in Treatment-Naive and Relapsed/Refractory High-Risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML). 62nd Annual Meeting & Exposition.. Blood 136(Suppl 1):39-40, 2020.
4. Guillermo Garcia-Manero, Michael R. Kurman, Courtney D. DiNardo, Naveen Pemmaraju, Yesid Alvarado, Kiran Naqvi, Farhad Ravandi, Elias J. Jabbour, Ricardo Delumpa, Timothy Madden, Gary Maier, Hiroyuki Iwamura, Hagop M. Kantarjian. Results of a Phase 1, Dose-Escalation Study of FF-10501-01 in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) or Hypomethylating Agent (HMA)-Resistant Myelodysplastic Syndrome (MDS). Blood 132(Suppl 1):1438, 2018.
5. Iman Aboudalle, Hagop M. Kantarjian, Nicholas J Short, Maria Khouri, Koichi Takahashi, Maro N. Ohanian, Gautam Borthakur, Marina Y. Konopleva, Naval G. Daver, Zeev E. Estrov, Yesid Alvarado , Nitin Jain, Farhad Ravandi, Guillermo Garcia-Manero, Michelle Velasquez, Patrice Nasnas, Susan M. O'Brien, Elias J. Jabbour. Phase II Study of Blinatumomab in Patients with B-Cell Lineage Acute Lymphocytic Leukemia with Positive Minimal/Measurable Residual Disease. Blood 132(Suppl 1):5212, 2018.
6. Sarah Bannon, Mark Routbort, Guillermo Garcia-Manero, Naval G. Daver, Betul Oran, Gautam Borthakur, Rohtesh S. Mehta, Kiran Naqvi, Koichi Takahashi, Yesid Alvarado, Tapan M. Kadia, Hagop M. Kantarjian, Keyur P. Patel, Courtney D. DiNardo. Next-Generation Sequencing of DDX41 in Myeloid Neoplasms Leads to Increased Detection of Germline Alterations. Blood 132(Suppl 1):2667, 2018.
7. Shyamala C. Navada, Guillermo Garcia-Manero, Ehab L. Atallah, M. Nabeel Rajeh, Jamile M. Shammo, Elizabeth A. Griffiths, Samer K. Khaled, Shaker R. Dakhil, David E. Young, Rosalie Odchimar-Reissig, Naveen Pemmaraju, Yesid Alvarado, Maro N. Ohanian, Rosmy B. John, Patrick S. Zbyszewski, Manoj Maniar, Michael E. Petrone, Steven M. Fruchtman, Lewis R. Silverman. Phase 2 Expansion Study of Oral Rigosertib Combined with Azacitidine (AZA) in Patients (Pts) with Higher-Risk (HR) Myelodysplastic Syndromes (MDS): Efficacy and Safety Results in HMA Treatment Naïve & Relapsed (Rel)/Refractory (Ref) Patients. Blood 132(Suppl 1):259, 2018.
8. Kelly S. Chien, Christopher B. Benton, Ayalew Tefferi, José Rodríguez, Farhad Ravandi, Naval G. Daver, Elias J. Jabbour, Nitin Jain, Yesid Alvarado, Monica Kwari, Sherry A. Pierce, Abhishek Maiti, Marisa J Hornbaker, Margarida Almeida Santos, Sara Martinez, Mariano Siguero, Darci Zblewski, Aref Al-Kali, William J. Hogan, Hagop M. Kantarjian, Animesh Pardanani, Guillermo Garcia-Manero. Safety and Tolerability of Lurbinectedin (PM01183) in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome. Blood 132(Suppl 1):2722, 2018.
9. Caitlin R. Rausch, Shilpa Paul, Guillermo Montalban Bravo, Elias J. Jabbour, Naval G. Daver, Alvarado Y, Courtney D. DiNardo, Farhad Ravandi, Gautam Borthakur, Prithviraj Bose, Naveen Pemmaraju, Kiran Naqvi, Steven M. Kornblau, Jorge E. Cortes, Tapan M. Kadia, Marina Y. Konopleva, Maro N. Ohanian, Sherry A. Pierce, Yvonne Gasior, Christopher B. Benton, Nitin Jain, Koichi Takahashi, Lucia Masarova, Michael Andreeff, Zeev E. Estrov, Hagop M. Kantarjian, Guillermo Garcia-Manero. Pattern of Immune-Mediated Toxicities in Patients with Myelodysplastic Syndrome (MDS) Treated with Nivolumab and Ipilimumab. Blood 132(Suppl 1):4367, 2018.
10. Farhad Ravandi, Sherry A. Pierce, Guillermo Garcia-Manero, Tapan M. Kadia, Elias J. Jabbour, Gautam Borthakur, Courtney D. DiNardo, Naval G. Daver, Nicholas J Short, Yesid Alvarado, , Jorge E. Cortes, Christopher Kim, Michael A Kelsh, Aaron Jacob Katz, Richard Williams, Zhao Yang, Bhakti Mehta, Hagop M. Kantarjian. Salvage Therapy Outcomes in a Historical Cohort of Patients with Relapsed or Refractory Acute Myeloid Leukemia. Blood 132(Suppl 1):3985, 2018.
11. Iman Aboudalle, Hagop M. Kantarjian, Maro N. Ohanian, Yesid Alvarado, Elias J. Jabbour, Guillermo Garcia-Manero, Kiran Naqvi, William G. Wierda, Naval G. Daver, Jan A. Burger, Marina Y. Konopleva, Koichi Takahashi, Michael Andreeff, Naveen Pemmaraju, Alessandra Ferrajoli, Gautam Borthakur, Tapan M. Kadia, Farhad Ravandi, Jorge E. Cortes. Phase I-II Study of Crenolanib Combined with Standard Salvage Chemotherapy and Crenolanib Combined with 5-Azacitidine in Acute Myeloid Leukemia Patients with FLT3 Activating Mutations. Blood 132(Supple 1):2715, 2018.
12. Guillermo Garcia-Manero, Guillermo Montalban-Bravo, Koji Sasaki, Naval G. Daver, Elias J. Jabbour, Yesid Alvarado , Courtney D. DiNardo, Farhad Ravandi, Gautam Borthakur, Prithviraj Bose, Naveen Pemmaraju, Kiran Naqvi, Jorge E. Cortes, Tapan M. Kadia, Marina Y. Konopleva, Caitlin R. Rausch, Yvonne Gasior, Hagop M. Kantarjian. You have access Double Immune Checkpoint Inhibitor Blockade with Nivolumab and Ipilimumab with or without Azacitidine in Patients with Myelodysplastic Syndrome (MDS). Blood 132(Suppl 1):1831, 2018.
13. Nicholas J Short, Elias J. Jabbour, Farhad Ravandi, Xuelin Huang, Nitin Jain, Koji Sasaki, Naveen Pemmaraju, Naval G. Daver, Joseph David Khoury, Jeffrey L. Jorgensen, Yesid Alvarado, Marina Y. Konopleva, Guillermo Garcia-Manero, Tapan M. Kadia, Musa Yilmaz, Gautam Borthakur, Jan A. Burger, Steven M. Kornblau, William G. Wierda, Courtney D. DiNardo, Alessandra Ferrajoli, Patrice Nasnas, Jovitta Jacob, Rebecca E. Garris, Susan M. O'Brien, Hagop M. Kantarjian. Chemoimmunotherapy with Inotuzumab Ozogamicin Combined with Mini-Hyper-CVD, with or without Blinatumomab, for Newly Diagnosed Older Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: Results from a Phase II Study. Blood 132(Suppl 1):36, 2018.
14. Guillermo Garcia-Manero, Koji Sasaki, Guillermo Montalban-Bravo, Kristy R. Bodden, Prithviraj Bose, Yesid Alvarado, Naval G. Daver, Gautam Borthakur, Farhad Ravandi, Koichi Takahashi, Jorge E. Cortes, Elias J. Jabbour, Kiran Naqvi, Courtney D. DiNardo, Christopher B. Benton, Naveen Pemmaraju, Tapan M. Kadia, Maro N. Ohanian, Sherry A. Pierce and Hagop M. Kantarjian. Final Report of a Phase II Study of Guadecitabine (SGI-110) in Patients (pts) with Previously Untreated Myelodysplastic Syndrome (MDS). Blood 132(Suppl 1):232, 2018.
15. Guillermo Garcia-Manero, Koji Sasaki, Guillermo Montalban-Bravo, Naval G. Daver, Elias J. Jabbour, Yesid Alvarado , Courtney D. DiNardo, Farhad Ravandi, Gautam Borthakur, Prithviraj Bose, Naveen Pemmaraju, Kiran Naqvi, Jorge E. Cortes, Tapan M. Kadia, Marina Y. Konopleva, Simona Colla, Hui Yang, Caitlin R. Rausch, Yvonne Gasior, Carlos E. Bueso-Ramos, Rashmi Kanagal-Shamanna, Keyur P. Patel, Hagop M. Kantarjia. A Phase II Study of Nivolumab or Ipilimumab with or without Azacitidine for Patients with Myelodysplastic Syndrome (MDS). Blood 132(Suppl 1):465, 2018.
16. Naval G. Daver, Guillermo Garcia-Manero, Sreyashi Basu, Jorge E. Cortes, Farhad Ravandi, Tapan M. Kadia, Marina Y. Konopleva, Elias J. Jabbour, Courtney D. DiNardo, Rita Assi, Sherry A. Pierce<b> Yesid Alvarado</b>, , Zeev E. Estrov, Naveen Pemmaraju, Koichi Takahashi, Jing Ning, Graciela M. Nogueras González, Steven M. Kornblau, Mansour Alfayez, Jairo Matthews, Wilmer Flores, Jorge Blando, James P Allison, Padmanee Sharma, Hagop M. Kantarjian. Safety, Efficacy, and Biomarkers of Response to Azacitidine (AZA) with Nivolumab (Nivo) and AZA with Nivo and Ipilimumab (Ipi) in Relapsed/Refractory Acute Myeloid Leukemia: A Non-Randomized, Phase 2 Study. Blood 132(Suppl 1):906, 2018.
17. Rita Assi, Hagop M. Kantarjian, Naval G. Daver, Guillermo Garcia-Manero, Christopher B. Benton, Philip A. Thompson, Gautam Borthakur, Tapan M. Kadia, Yesid Alvarado, Elias J. Jabbour, Marina Y. Konopleva, Koichi Takahashi, Steven M. Kornblau, Courtney D. DiNardo, Zeev E. Estrov, Wilmer Flores, Sreyashi Basu, James P Allison, Padmanee Sharma, Sherry A. Pierce, Allison Pike, Jorge E. Cortes, Farhad Ravandi. Results of a Phase 2, Open-Label Study of Idarubicin (I), Cytarabine (A) and Nivolumab (Nivo) in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS). Blood 132(Suppl 1):905, 2018.
18. Prithviraj Bose, David McCue, Nathan P. Wiederhold, Tapan M. Kadia, Gautam Borthakur, Farhad Ravandi, Musa Yilmaz, Koichi Takahashi, Philip A. Thompson, Naveen Pemmaraju, Naval G. Daver, Jan A. Burger, Jorge E. Cortes, Guillermo Garcia-Manero, Srdan Verstovsek, Marina Y. Konopleva, Nitin Jain, Courtney D. DiNardo, Yesid Alvarado , Kiran Naqvi, Steven M. Kornblau, Alessandra Ferrajoli, William G. Wierda, Zeev E. Estrov, Christopher B. Benton, Lucia Masarova, Guillermo Montalban-Bravo, Koji Sasaki, Caitlin R. Rausch, Kayleigh Marx, Wei Qiao, Xuelin Huang, Carol A. Bivins, Sherry A. Pierce, Hagop M. Kantarjian, Dimitrios P. Kontoyiannis. Isavuconazole (ISAV) As Primary Anti-Fungal Prophylaxis in Acute Myeloid Leukemia or Myelodysplastic Syndrome: An Open-Label, Prospective Study. Blood 132(Suppl 1):2674, 2018.
19. Nicholas J Short, Hagop M. Kantarjian, Sanam Loghavi, Xuelin Huang, Wei Qiao, Gautam Borthakur, Tapan M. Kadia, Naval G. Daver, Maro N. Ohanian, Courtney D. DiNardo, Zeev E. Estrov, Rashmi Kanagal-Shamanna, Abhishek Maiti, Christopher B. Benton, Prithviraj Bose, Yesid Alvarado, , Elias J. Jabbour, Steven M. Kornblau, Naveen Pemmaraju, Nitin Jain, Yvonne Gasior, Mary Ann Richie, Sherry A. Pierce, Jorge E. Cortes, Marina Y. Konopleva, Guillermo Garcia-Manero, Farhad Ravandi. Five-Day Versus Ten-Day Schedules of Decitabine in Older Patients with Newly Diagnosed Acute Myeloid Leukemia: Results of a Randomized Phase II Study. Blood 132(Suppl 1):84, 2018.
20. Abhishek Maiti, Courtney D. DiNardo, Jorge E. Cortes, Gautam Borthakur, Naveen Pemmaraju, Christopher B. Benton, Tapan M. Kadia, Koichi Takahashi, Kiran Naqvi, Farhad Ravandi, Alvarado Y , Nicholas J Short, Naval G. Daver, Koji Sasaki, Maro N. Ohanian, Guillermo Garcia-Manero, Philip A. Thompson, Steven M. Kornblau, Lucia Masarova, Nitin Jain, Elias J. Jabbour, Michael Andreeff, Rita Maduike, Julio A Guerrero, Qi Zhang, Antonio Cavazos, Helen Ma, Caitlin R. Rausch, Carol A. Bivins, Kenneth Vaughan, Sherry A. Pierce, Jing Ning, Wei Qiao, John S. Welch, Hagop M. Kantarjian, Marina Y. Konopleva. Interim Analysis of Phase II Study of Venetoclax with 10-Day Decitabine (DEC10-VEN) in Acute Myeloid Leukemia and Myelodysplastic Syndrome. Blood 132(Suppl 1):286, 2018.
21. Kiran Naqvi, Graciela M. Nogueras - Gonzalez, Cora M. Cheung, Naveen Pemmaraju, Elias Jabbour, Guillermo Garcia - Manero, Courtney DiNardo, Maro Ohanian, Nitin Jain, Koichi Takahashi, Yesid Alvarado, Marina Konopleva, Xue;om Huang, Jorge E. Cortes, Hagop Kantarjian. A bayesian randomized phse II study of guadecitabine (SGI-110) based regimens comparing guadecitabine 5 days (SGI5), 10 days (SGI10), 5 days + Idarubicin (SGI5 = Ida), 5 days + cladribine(SGI5+ Clad), in untreated patien >/= 70years with acute myeloid leukemia (AML). Journal Of Clinical Oncology, 2017.
22. Nicholas Short, Hagop Kantarjian, Susan M. O'Brien, Farhad Ravandi, Deborah A. Thomas, Guillermo Garcia - Manero, Naval Daver, Gautam Borthakur, Nitin Jain, Marina Konopleva, Koji Sasaki, Naveen Pemmaraju, Yesid Alvarado, Jovitta Jacob, Rebecca Garris, Philip A. Thompson, Jorge E. Cortes, Elias Jabbour. Updated results of a phase I/II study of inotuzumab ozogamicin in combination with low - intensity chemotherapy (mini-hyper-CVD) as frontline therapy for older patients with acute lymphoblastic leukemia. Journal Of Clinical Oncology, 2017.
23. Christopher Benton, Jose Rodriguez Diaz - Pavon, Abhishek Maiti, Naval Daver, Farhad Ravandi, Nitin Jain, Yesid Alvarado, Elias Jabbour, Sherry Pierce, Monica Kwari, Margarida A. Santos, Sara Martinez, Mariano Siguero, Ayalew Tefferi, Jorge E. Cortes, Hagop Kantarjian, Animesh Dev Pardanani, Guillermo Garcia - Manero. Phase I study of lurbinectedin (PM11083) in patients with advanced AML and MDS. Journal Of Clinical Oncology, 2017.
24. Prajwai boddu, Jeffrey L. Jorgenson, Hagop Kantarjian, Gautam Borthakur, Tapan Kadia, Naval G. Daver, Yesid Alvarado, Naveen Pemmarju, Prtihviraj Bose, Kiran Naqvi, Musa Yilmaz, Sherry Pierce, Mark Brandt, Courtney DiNardo, Elias Jabbour, Guillermo Garcia - Manero, Jorge E. Cortes, Farhard Ravandi. Achievement of a negative minimak residual disease state after hypomethylating agent therapy in older patients with AML to reduce risk of relapse. Journal Of Clinical Oncology, 2017.
25. Shyamala C. Navada, Guillermo Garcia- manero, Katherin P. Hearn, Rosalie Odchimar - Reissigm Erin P. Demakos, Yesid Alvarado, Naval Daver, Courtney D. DiNardo, Marina Konopleva, Gautam Borthakur, Pierre Fenaux, Michael E. Petrone, Patrick Simon Zbyszewski, Steven M. Fruchtman, Lewis Silverman. Combination of Oral Rigosertib and Injectable Azacitidine in Patient with Myelodysplastic Syndromes (MDS): Results from a Phase || Study. Blood, 2016.
26. Koji Sasaki, Elias Jabbour, Susan O'Brien, Farhad Rvandi, Deborah A. Thomas, Tapan Kadia, Guillmero Garcia - Manero, Jan A. Burger, Naveen Pemmaraju, Yesid Alvarado, Naval Daver, Nitin Jain, Marina Konopleva, Richard E. Champlin, Issa F. Khouri, Jovitta Jacob, Rebecca Garris, Jorge E. Cortes, Hagop Kantarjian. Phase II Study of the Salvage Mini - Hyper - CVD in Combination with Inotuzumab Ozogamicin (INO) for Adult Patients with Relapsed/Refractory (R/R) Acute lymphoblastic Leukemia (ALL). Blood, 2016.
27. Guillermo Montalban - Bravo, Xuelin Huang, Elias Jabbour, Gautam Borhtakur, Courtney D. DiNardo, Naveen Pemmaraju, Jorge E. Cortes, Srdan Verstovsek, Tapan M. Kadia, Naval G. Daver, William G. Wierda, Yesid Alvarado, Marina Konopleva, Farhad Ravandi, Zeev Estrov, Nitin Jain, Ana Alfonso Pierola, Mark Brandt, Troy Sneed, Hsiany-Chun Chen, Hui Yang, Carlos E. Bueso - Ramos, Sherry Pierce, Elihu H. Estey, Zachary S. Bohannan, Hagop Kantarjian, Guillermo Garcia - Manero. A Phase II Clinical Trial of Azacitidine and Vorinostat for Patients with Acute Myeloid Leukemia. Blood, 2016.
28. Elias Jabbour, Nicholas J. Short, Xuelin Huang, Abhishek maiti, Tapan M. Kadia, Navak Daver, Gautam Borthakur, Courtney D. DiNardo, Naveen Pemmaraju, Koji Sasaki, Zeev Estrov, Srdan Verstovsek, Farhad Ravandi, Yesid Alvarado, Mikkael A. Sekeres, Rami S. Komrokji, David P. Steensma, Amy E. DeZern, Gail J. Roboz, Darla Miller, Xiao Dong, Hagop Kantarjian, Guillermo Garcia - Manero. A Ramdomized Phase II Study of Low - Dose Decitabine Versus Azacitidine in Patients with Low - or Intermediate - 1 - Risk Myelodysplastic Syndromes: A Report on Behalf of the MDS Clinical Research Consortium. Blood, 2016.
29. Nicholas Short, Guillermo Garcia - Manero, Kiran Naqvi, Steven Kornblau, Abhishek Nautu, Marina Konopleva, Courtney D. DiNardo, Koichi Takahashi, Yesid Alvarado, Maro Ohanian, Zeev Estrov, Prithviraj Bose, Michael Andreeff, Rabiul Islam, Xiao Dong, Jorge E. Cortes, Hagop Kantarjian, Eilas Jabbour. A Phase II Trial of Omacetaxine Mepesuccinate for Patients with High - Risk Myelodysplastic Syndrome after Failure of Hypomethylating Agents. Blood, 2016.
30. Prithviraj Bose, Srdan Verstovsek, Yvonne Gasior, Nitin Jain, Elias Jabbour, Zeev Etrov, Yesid Alvarado, Courtney D. DiNardo, Naveen Pemmarajum Steven M. Kornblau, Tapan M. Kadia, Naval G. Daver, Mark Brandt, Sherry Pierce, Graciela M. Nogueras - Gonzalez, Xuelin Huang, Guillermo Garcia - Manero , Hagop Kantarjian, Farhad Ravandi. Phase I/II Study of Ruxolitinib (RUX) wutg Decutabine (DAC) in Patients with Post - Myeloproliferative Neoplasm Acute Myeloid Leukemia (post - MPN AML): Phase I Results. Blood, 2016.
31. Tapan Kadia, Jorge E. Cortes, Elias Jabbour, Naval Daver, Naveen Pemmarju, Farhad Ravandi, Nitin Jain, Srdan Verstovsek, Courtney DiNardo, Yesid Alvarado, Alessandra Ferrajoli, Jan A. Burger, Guillermo Garcia - Manero, Maro Ohanian, Marina Konopleva, Zeev Estrov, William Wierda, Mark Brandt, Tina Fitch, Gautam Borthakur, Hagop Kantarjian. Phase II Study of Cladribine, Idarubicin, and Cytarabine (araC) in Patients with Acute Myeloid Leukemia (AML). Blood, 2015. e-Pub 2015.
32. Maliha Khan, Kristy Bodden, Tapan Kadia, Alessandra Ferrajoli, Yesid Alvarado , Gautam Borthakur, Naveen Pemmaraju, Marina Konopleva, Guillermo Garcia - Manero, Courtney DiNardo. Efficacy and Safety of Eltrombopag for Treatment of Patients with Myelodysplastic Syndromes after Hypomethylating - Agent Failure: A Phase 2 Clinical Trial. Blood, 2015.
33. Alvarado Y, Kantarjian H, Ravandi F, Luthra R, Borthakur G, Garcia - Manero G, Faderl S, Konopleva M, Estrov Z, Andreeff M, Cortes J. FLT3 Inhibitor treatment in FLT3-mutated AML is Associated with development of secondary FLT3-TKD mutations. 53rd ASH Annual Meeting. Blood 118, 2011.
34. Liu - Dumlao T, Kantarjian H, Quintas - Cardama A, Jabbour E, Burger J, Alvarado Y, Burton E, Trinh L, Ravandi F, Ferrajoli A, O'Brien S, Cortes J,. Clinical significance of myelosuppression associated with the use of Dasatinib and Nilotinib as initial therapy in chronic phase of Chronic Myeloid Leukemia. 53rd ASH Annual Meeting. Blood 118, 2011.
35. Ault P, Kantarjian H, Bryan J, Prescot H, Alvarado Y , Fava C, Cortes J. Clinical use of imatinib plasma levels in patients with chronic myeloid leukemia. 48th ASH Annual Meeting. Blood 112:4255, 2008.
36. Alvarado Y, Kantarjian H, Verma D, Mattiuzzi G, Aribi A, Ravandi F, Borthakur G, Cortes J. Long-term prognostic impact of the use of erythropoiesis-stimulating agents (ESA) in patients (pts) with chronic myeloid leukemia (CML) treated with imatinib. 49th ASH Annual Meeting, 2007.
37. Alvarado Y, Kantarjian H, Faderl S, Burger J, Borthakur G, O’Brien S, Wierda W, Garcia-Manero G, Cortes J. Significance of Suboptimal Response to Imatinib, as Defined by the European LeukemiaNet, in Long-Term Outcome for Patients (Pts) with Chronic Phase (CP) Chronic Myeloid Leukemia (CML). 49th ASH Annual Meeting, 2007.
38. Alvarado Y, Kantarjian H, Freireich EJ, Garcia-Manero G, Ferrajoli A, Koller C, Estrov Z, Kornblau S, Laddie N, Smith L, Cortes J. Phase II dosing study of cytarabine chemotherapy in combination with cenersen (EL625) and idarubicin in refractory and relapsed acute myelogenous leukemia (AML). ASCO National Annual Meeting, 2007.
39. Alvarado Y, Brown R, DiPiersio J, Verstovsek S, Cortes J, O’Brien S, Sznol M, Kantarjian H, Fracasso P, Giles F. Phase I study of Triapine, a novel ribonuclotide reductase inhibitor (RRI), in patients with refractory hematologic malignancies. 44th ASH Annual Meeting. Leukemia Research 27(12):1077-1083, 2003.
40. Alvarado Y, Kantarjian H, Cortes J, Verstovsek S, Faderl S, Garcia-Manero G, Tsimberidou A, Sznol M, Giles F. Phase I Study of VNP40101M, a novel alkylating agent in patients with refractory hematologic malignancies. ASCO National Annual Meeting, 2003.
41. Waddelow T, Mattiuzzi G, Alvarado Y, Giles F, Estey E. Rate of infections Associated with Gemtuzumab (GO) vs. Non-Gemtuzumab Therapy in patients with Acute Myelogenous Leukemia (AML) or myelodysplastic Syndrome (MDS). 43rd ASH Annual Meeting, 2001.
42. Waddelow T, Mattiuzzi G, Alvarado Y, Giles F, Estey E. Rate of infections Associated with Gemtuzumab (GO) vs. Non-Gemtuzumab Therapy in patients with Acute Myelogenous Leukemia (AML) or myelodysplastic Syndrome (MDS), 2001.